古典的薬理学 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "古典的薬理学" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

low place

low place

1books.google.com

3^rd place

61^st place

books.google.com

Bachmann KA, Hacker MP, Messer W (2009). Pharmacology principles and practice. Amsterdam: Elsevier/Academic Press. p. 576. ISBN 978-0-12-369521-5

doi.org

Takenaka T (September 2001). “Classical vs reverse pharmacology in drug discovery”. BJU Int. 88 Suppl 2: 7–10; discussion 49–50. doi:10.1111/j.1464-410X.2001.00112.x. PMID 11589663.
Lazo JS (April 2008). “Rear-view mirrors and crystal balls: a brief reflection on drug discovery”. Mol. Interv. 8 (2): 60–3. doi:10.1124/mi.8.2.1. PMID 18403648.
Vogt A, Lazo JS (August 2005). “Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets”. Pharmacol. Ther. 107 (2): 212–21. doi:10.1016/j.pharmthera.2005.03.002. PMID 15925410.
Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ (May 2012). “Modern phenotypic drug discovery is a viable, neoclassic pharma strategy”. J. Med. Chem. 55 (10): 4527–38. doi:10.1021/jm201649s. PMID 22409666.
Patwardhan B; Vaidya ADB. Chorghade M; Joshi SP (2008). “Reverse Pharmacology and Systems Approaches for Drug Discovery and Development”. Current Bioactive Compounds 4 (4): 201–212. doi:10.2174/157340708786847870.
Vaidya ADB (2006). “Reverse pharmacological correlates of ayurvedic drug actions”. Indian Journal of Pharmacology 38 (5): 311. doi:10.4103/0253-7613.27697.
Pathak N (April 2011). “Reverse pharmacology of Ayurvedic drugs includes mechanisms of molecular actions”. J Ayurveda Integr Med 2 (2): 49–50. doi:10.4103/0975-9476.82512. PMC 3131769. PMID 21760686.
Lele RD (October 2010). “Beyond reverse pharmacology: Mechanism-based screening of Ayurvedic drugs”. J Ayurveda Integr Med 1 (4): 257–65. doi:10.4103/0975-9476.74435. PMC 3117317. PMID 21731372.
Willcox ML, Graz B, Falquet J, Diakite C, Giani S, Diallo D (March 2011). “A "reverse pharmacology" approach for developing an anti-malarial phytomedicine”. Malar. J. 10 Suppl 1: S8. doi:10.1186/1475-2875-10-S1-S8. PMC 3059466. PMID 21411019.
Patwardhan B; Vaidya ADB. Chorghade M; Joshi SP (2008). “Reverse Pharmacology and Systems Approaches for Drug Discovery and Development”. Current Bioactive Compounds 4 (4): 201–212. doi:10.2174/157340708786847870.
Willcox ML, Graz B, Falquet J, Diakite C, Giani S, Diallo D (March 2011). “A "reverse pharmacology" approach for developing an anti-malarial phytomedicine”. Malar. J. 10 Suppl 1: S8. doi:10.1186/1475-2875-10-S1-S8. PMC 3059466. PMID 21411019.

iaim.edu.in

Patwardhan B; Vaidya ADB. Chorghade M; Joshi SP (2008). “Reverse Pharmacology and Systems Approaches for Drug Discovery and Development”. Current Bioactive Compounds 4 (4): 201–212. doi:10.2174/157340708786847870.
Patwardhan B; Vaidya ADB. Chorghade M; Joshi SP (2008). “Reverse Pharmacology and Systems Approaches for Drug Discovery and Development”. Current Bioactive Compounds 4 (4): 201–212. doi:10.2174/157340708786847870.

nih.gov

pubmed.ncbi.nlm.nih.gov

Takenaka T (September 2001). “Classical vs reverse pharmacology in drug discovery”. BJU Int. 88 Suppl 2: 7–10; discussion 49–50. doi:10.1111/j.1464-410X.2001.00112.x. PMID 11589663.
Lazo JS (April 2008). “Rear-view mirrors and crystal balls: a brief reflection on drug discovery”. Mol. Interv. 8 (2): 60–3. doi:10.1124/mi.8.2.1. PMID 18403648.
Vogt A, Lazo JS (August 2005). “Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets”. Pharmacol. Ther. 107 (2): 212–21. doi:10.1016/j.pharmthera.2005.03.002. PMID 15925410.
Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ (May 2012). “Modern phenotypic drug discovery is a viable, neoclassic pharma strategy”. J. Med. Chem. 55 (10): 4527–38. doi:10.1021/jm201649s. PMID 22409666.
Pathak N (April 2011). “Reverse pharmacology of Ayurvedic drugs includes mechanisms of molecular actions”. J Ayurveda Integr Med 2 (2): 49–50. doi:10.4103/0975-9476.82512. PMC 3131769. PMID 21760686.
Lele RD (October 2010). “Beyond reverse pharmacology: Mechanism-based screening of Ayurvedic drugs”. J Ayurveda Integr Med 1 (4): 257–65. doi:10.4103/0975-9476.74435. PMC 3117317. PMID 21731372.
Willcox ML, Graz B, Falquet J, Diakite C, Giani S, Diallo D (March 2011). “A "reverse pharmacology" approach for developing an anti-malarial phytomedicine”. Malar. J. 10 Suppl 1: S8. doi:10.1186/1475-2875-10-S1-S8. PMC 3059466. PMID 21411019.
Willcox ML, Graz B, Falquet J, Diakite C, Giani S, Diallo D (March 2011). “A "reverse pharmacology" approach for developing an anti-malarial phytomedicine”. Malar. J. 10 Suppl 1: S8. doi:10.1186/1475-2875-10-S1-S8. PMC 3059466. PMID 21411019.
Patwardhan B, Vaidya AD (2010). “Natural products drug discovery: accelerating the clinical candidate development using reverse pharmacology approaches”. Indian J. Exp. Biol. 48 (3): 220–7. PMID 21046974.

ncbi.nlm.nih.gov